Board Meeting On May 30, 2017
Intimation Regarding Board Meeting for the Audited Consolidated and Standalone Financial Result for the Quarter and Year Ended on March 31, 2017 and closure of Trading Window20-05-2017
20-05-2017
Shareholding for the Period Ended March 31, 2017
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here19-04-2017
Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015
Certificate From Practicing Company Secretary under Regulation 40 (9) of SEBI (LODR) Regulations, 2015 for the half year ended on March 31, 201718-04-2017
Statement Of Investor Complaints For The Quarter And Year Ended On March 31, 2017
We Submitted herewith the Compliance on Statement of Investor Complaints of Lincoln Pharmaceuticals Limited for the quarter and ended on March 31, 201718-04-2017
Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2016
Lincoln Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Consolidated Financial Results for the period ended December 31, 20163. Standalone Limited Review for the period ended December 31, 20164. Consolidated Limited Review for the period ended December 31, 201609-02-2017
Board Meeting Intimation for Results & Closure of Trading Window
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on February 09, 2017, to consider and approve the Un-audited Consolidated and Standalone Financial Results of the Company for the Quarter ended on December 31, 2016.In view of above, the trading window will remain close for the Promoters, Directors, Insiders, Designated Persons and the Connected Persons from the date...30-01-2017
Shareholding for the Period Ended December 31, 2016
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here19-01-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Lincoln Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.12-01-2017
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Patel Nishitkumar Maheshbhai31-12-2016
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Patel Nishitkumar Maheshbhai30-12-2016